

Next Generation Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

Market Report | 2024-11-06 | 144 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

Report description:

The Global Next Generation Cancer Diagnostics Market reached USD 15.5 billion in 2023 and is projected to grow at a 10% CAGR from 2024 to 2032. The surge in demand is primarily fueled by the shift towards personalized medicine, which tailors treatments based on individual genetic and molecular data. Advanced diagnostic technologies, including next-generation sequencing (NGS) and liquid biopsy, are central to identifying genetic mutations and specific cancer biomarkers. These capabilities enhance early detection and optimize targeted therapy selection.

Next-generation cancer diagnostics introduce advanced tools and techniques enabling precise, early detection and personalized cancer analysis. These advancements improve disease monitoring and risk assessment, allowing for the refined selection of targeted therapies. By focusing on the unique genetic, molecular, and cellular characteristics of tumors, this market is leading a revolution in cancer care, driven by precision medicine's potential to achieve better clinical outcomes and more effective treatment.

The market is divided into products and services, with the products segment taking a significant share and expected to grow at a 9.8% CAGR over the forecast period. This segment includes instruments and kits & consumables, all essential for diagnostic accuracy and efficiency. Demand is high for advanced sequencing platforms, PCR machines, and imaging devices used widely across hospitals, laboratories, and research institutions, contributing significantly to market revenue.

Technologically, the next generation cancer diagnostics market from the NGS segment held 32.5% share in 2023 due to its ability to provide detailed genomic insights quickly and accurately. NGS's role in identifying genetic mutations and biomarkers is vital for early cancer detection and personalized treatment, with growing cancer prevalence, NGS innovations, and decreasing costs driving adoption.

In the U.S., the next-generation cancer diagnostics market is set to grow at a 9.5% CAGR through 2032. The country leads the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market due to its advanced healthcare infrastructure, substantial R&D investments, and emphasis on innovation. The presence of prominent biotechnology and pharmaceutical firms, strong government backing for cancer research, and increased public awareness of early detection reinforces the U.S.'s position in this rapidly evolving field.

Table of Contents:

Report Content

Chapter 1 Methodology & Scope

1.1 Market scope & definition

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates & calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence of cancer

3.2.1.2 Growing advancement in diagnostic technologies

3.2.1.3 Increased investments in cancer research

3.2.1.4 Growing awareness and screening programs

3.2.2 Industry pitfalls & challenges

3.2.2.1 High costs of advanced diagnostics technologies

3.2.2.2 Stringent regulations and lengthy approval processes

3.3 Growth potential analysis

3.4 Future market trends

3.5 Technology landscape

3.6 Pricing analysis

3.7 Regulatory landscape

3.8 Porter's analysis

3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction

4.2 Company matrix analysis

4.3 Company market share analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Strategy dashboard

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 (\$ Mn)

5.1 Key trends

5.2 Products

5.2.1 Instruments

5.2.2 Kits & consumables

5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 (\$ Mn)

6.1 Key trends

6.2 Next-generation sequencing (NGS)

6.3 Polymerase chain reaction (PCR)

6.4 DNA microarrays

6.5 Multiplexing

6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 (\$ Mn)

7.1 Key trends

7.2 Breast cancer

7.3 Lung cancer

7.4 Colorectal cancer

7.5 Prostate cancer

7.6 Cervical cancer

7.7 Liver cancer

7.8 Other cancer types

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 (\$ Mn)

8.1 Key trends

8.2 Screening and early detection

8.3 Prognostics and monitoring

8.4 Therapy selection

8.5 Recurrence monitoring

8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 (\$ Mn)

9.1 Key trends

9.2 Hospitals & clinics

9.3 Diagnostic laboratories

9.4 Academic & research institutions

9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 (\$ Mn)

10.1 Key trends

10.2 North America

10.2.1 U.S.

10.2.2 Canada

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 France

10.3.4 Italy

10.3.5 Spain

10.3.6 Netherlands

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4 Asia Pacific
 - 10.4.1 China
 - 10.4.2 Japan
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 South Korea
- 10.5 Latin America
 - 10.5.1 Brazil
 - 10.5.2 Mexico
 - 10.5.3 Argentina
- 10.6 Middle East and Africa
 - 10.6.1 South Africa
 - 10.6.2 Saudi Arabia
 - 10.6.3 UAE
- Chapter 11 Company Profiles
 - 11.1 Agilent
 - 11.2 Almac
 - 11.3 Bio-Rad Laboratories
 - 11.4 Exact Sciences
 - 11.5 F. Hoffmann-La Roche
 - 11.6 GenScript
 - 11.7 Guardant Health
 - 11.8 Illumina
 - 11.9 Karkinos Healthcare
 - 11.10 Qiagen
 - 11.11 Koninklijke Philips
 - 11.12 Thermo Fisher Scientific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Next Generation Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

Market Report | 2024-11-06 | 144 pages | Global Market Insights

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com